Abstract
This study evaluated the efficacy of PCV2a and PCV2d vaccines against a PCV2 challenge. Three-week-old, cesarean-derived, colostrum-deprived pigs were blocked by litter and randomized to treatment group. Pigs received a single 2 mL intramuscular dose of either placebo (PLAC, n=50), PCV2a vaccine (PCV2aV, n=25), or PCV2d vaccine (PCV2dV, n=25) on D0 and were challenged with a PCV2d isolate on D28. Prior to challenge, a naturally occurring PCV2a infection was identified. Both vaccines similarly prevented lymphoid tissue lesions, mortality and clinical signs of PCVAD while PLAC pigs were severely affected. Viremia was significantly reduced 7, 14, 21, and 28 days post-challenge and average daily weight gain was significantly increased for both vaccine groups. The prevention of mortality and very minimal occurrence of lymphoid tissue lesions in both vaccine groups, provides clear evidence of the benefit of PCV2 vaccination in the face of a virulent mixed PCV2 challenge.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
